Prof. Peter Goadsby talks to us about premonitory-like symptomatology in migraine, the focus of his article recently published in European Neurological Review.
View his article here.
Speaker disclosures: nothing to disclose in relation to this video interview.
Filmed at the 3rd Congress of the European Academy of Neurology (EAN), Amsterdam, June 2017.
Trending Topic
Data from the REFORM trial (NCT04674020) provide valuable insights into cortical inflammation in adults with migraines, using a novel quantitative, multimodal MRI technique to compare these patients with age- and gender-matched healthy controls, enhancing our understanding of migraine biology and other headache disorders. The discussion also covers cluster headaches, focusing on a study that examines premonitory symptoms in affected individuals and highlights key phenotypic characteristics. Additionally, we explore findings from the European Migraine & Headache Alliance on the stigma surrounding migraines, which yield insightful and actionable results. Looking ahead, the focus shifts to the latest data on new medications for preventing and treating migraine attacks, discussing future prospects and identifying areas in headache disorder management that still need further attention.
In this touchNEUROLOGY interview, editorial board member Prof Peter Goadsby (King's college Hospital, London) highlights two presentations from the annual European Academy of Neurology (EAN), July 1–4, 2023, in the field of migraine; the first by Klein et al. looking at a ...
In this touchNEUROLOGY interview, editorial board member Prof Peter Goadsby (King's college Hospital, London) provides an overview of his top three most important clinical trial data and hot topics presented at the annual European Academy of Neurology (EAN), July 1–4, 2023, in ...
Prof Stewart Tepper (Geisal School of Medicine - Dartmouth, Hanover, NH, USA) summarizes the pivotal results of the PROGRESS phase 3 trial, evaluating the efficacy, safety, and tolerability of atogepant for preventive treatment of chronic migraine (CM). This study has very ...
Atogepant represents a relatively new class of medications called CGRP receptor antagonists, which have shown efficacy in preventing migraines. The PROGRESS phase 3 clinical trial assessed the efficacy of atogepant, an important new oral treatment option for the 8% of people with ...
Prof Stewart Tepper (Geisal School of Medicine - Dartmouth, Hanover, NH, USA) shares one the most exciting presentations from the 75th AAN Annual Meeting, 2023. The results of the PRODROME study represent a paradigm shift in headache management and the data ...
Migraine affects over 1 billion people worldwide causing significant disability and a socioeconomic burden. Preventive treatment is key to managing migraine, but it is often underutilized. Prof Stewart Tepper (Geisal School of Medicine - Dartmouth, Hanover, NH, USA) summarizes his presentation ...
Prof Stewart Tepper (Geisal School of Medicine - Dartmouth, Hanover, NH, USA) summarizes safety and tolerability data from the ASCEND study of STS101 5.2 mg (dihydroergotamine nasal powder) in the acute treatment of migraine attacks with/without aura over 12 months. STS101 ...
A better understanding of the key areas of unmet need regarding acute migraine therapy may help inform drug development and treatment selection. Prof Stewart Tepper (Geisal School of Medicine - Dartmouth, Hanover, NH, USA) summarizes a poster on data from ...
"Migraine is a common and complex brain disorder that affects 10 million people in the UK, impacting their ability to work, relationships and mental health. It’s poorly understood by the public and even many health professionals, and there are challenges ...
Headache is one of the most common nervous system disorders. In an interview with touchNEUROLOGY, Dr Raquel Gil-Gouveia (Hospital da Luz, Lisbon, Portugal) summarizes the ePoster session she chaired at EAN 2022, ranging from topics such as how COVID-19 has impacted ...
The limitations of the current treatment of acute migraine are said to be patient variability and migraine attack variability. Prof. Stewart Tepper (Dartmouth-Hitchcock Medical Centre, Lebanon, NH, USA) discusses the limitations of current treatments for acute migraine and how new ...
Keep track of your clinical interests and newsletter subscriptions.
Or use a .
Already registered? Login below.
